Brief: National Comprehensive Cancer Network Adds Newly Approved REZLIDHIA (Olutasidenib) To Clinical Practice Guidelines In Oncology
18/01/2023 13:25
Jan 18 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* NATIONAL COMPREHENSIVE CANCER NETWORK ADDS NEWLY APPROVED
REZLIDHIA (OLUTASIDENIB) TO CLINICAL PRACTICE GUIDELINES IN
ONCOLOGY FOR ACUTE MYELOID LEUKEMIA
Source text for Eikon: ID:nPn1ZLvYga
Further company coverage: RIGL.O
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)